Urinary System Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: URN009 MIFTS: 51	Urinary System Disease Categories: Cancer diseases, Nephrological diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Urinary System Disease

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease ¹¹ ¹⁴ ¹⁶

Abnormality of the Urinary System ²⁸ ⁵

Congenital Malformation of the Urinary System ⁷¹

Non-Neoplastic Urinary System Disorder ⁷¹

Non-Neoplastic Urinary Tract Disease ¹¹

Urinary Tract Diseases ⁵³

Urinary Tract Disease ¹¹

Urinary Tract Anomaly ⁵³

Urologic Diseases ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Congenital malformations, deformations and chromosomal abnormalities

Congenital malformations of the urinary system

Other congenital malformations of urinary system

Congenital malformation of urinary system, unspecified

Other specified congenital malformations of urinary system

Diseases of the genitourinary system

Other diseases of urinary system

Other disorders of urinary system

Disorder of urinary system, unspecified

Other specified disorders of urinary system

ICD11: ³³

Diseases of the genitourinary system

Diseases of the urinary system

Diseases of the urinary system, unspecified

External Ids:

Disease Ontology ¹¹ DOID:18

NCIt ⁴⁹ C27599

ICD10 ³¹ N39 N39.8 N39.9 more

EFO ¹⁶ EFO_0009690

ICD11 ³³ 1932345217 1932345217/unspecified

UMLS ⁷¹ C0042075 C0158698 C1335051

Sources

Summaries for Urinary System Disease

Disease Ontology: ¹¹ A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary: Urinary System Disease, also known as abnormality of the urinary system, is related to bladder disease and kidney disease, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are miRNAs involved in DNA damage response and Cell differentiation - expanded index. The drugs Levoleucovorin and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and brain.

Sources

Related Diseases for Urinary System Disease

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 453)

#	Related Disease	Score	Top Affiliating Genes
1	bladder disease	32.5	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
2	kidney disease	32.5	UMOD SIX1 NAGLU MIR21 MIR199A1 B2M
3	urinary tract infection	32.4	UMOD KLK3 H2AC18 CFHR2 CCR6
4	ureteral disease	32.4	UMOD MIR199A1 MIR142 CCR6
5	urinary tract obstruction	31.1	UMOD NAGLU MIR199A1 MIR142 KLK3 CCR6
6	vesicoureteral reflux	31.1	UMOD SIX1 NAGLU B2M
7	bladder cancer	31.0	MIR21 MIR199A1 MIR17 MIR145 KRT20 KLK3
8	lymphoma, non-hodgkin, familial	30.8	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
9	mycobacterium tuberculosis 1	30.7	MIR21 MIR155 MIR144 ICOSLG H2AC18 CCR6
10	viral infectious disease	30.7	MIR21 MIR199A1 MIR155 ICOSLG H2AC18 CCR6
11	wilms tumor 1	30.7	SIX1 MIR199A1 MIR193A MIR144 MIR142 ICOSLG
12	endometriosis	30.7	MIR199A1 MIR17 MIR145 MIR142 MIR126
13	hydronephrosis	30.7	NAGLU KLK3 B2M
14	acute kidney tubular necrosis	30.7	UMOD NAGLU CCR6 B2M
15	chronic kidney disease	30.7	UMOD MIR21 MIR126 CFHR2 CCR6 B2M
16	dermatitis, atopic	30.7	MIR21 MIR155 MIR142 ICOSLG CCR6
17	deficiency anemia	30.7	MIR126 ICOSLG H2AC18 CFHR2 CCR6 B2M
18	syphilis	30.6	MIR142 CCR6 B2M
19	cervical cancer	30.5	MIR30A MIR21 MIR193A MIR17 MIR155
20	hematuria, benign familial	11.0
21	cakut	11.0
22	urolithiasis	11.0
23	urethral syndrome	11.0
24	bacteriuria	11.0
25	lower urinary tract calculus	11.0
26	lung cancer	10.7	SIX1 MIR30A MIR21 MIR199A1 MIR193A MIR17
27	nervous system disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
28	type 2 diabetes mellitus	10.7	NAGLU MIR30A MIR21 MIR199A1 MIR193A MIR17
29	peripheral nervous system disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
30	leukocyte disease	10.7	MIR30A MIR21 MIR199A1 MIR17 MIR155 MIR145
31	bone marrow cancer	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
32	renal cell carcinoma, nonpapillary	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
33	leukemia, chronic lymphocytic	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
34	squamous cell carcinoma, head and neck	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
35	biliary tract disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
36	esophageal disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
37	bone disease	10.7	MIR30A MIR21 MIR199A1 MIR17 MIR155 MIR142
38	bile duct adenocarcinoma	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
39	ovary epithelial cancer	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
40	skin disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
41	bile duct disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
42	kidney cancer	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
43	autonomic nervous system neoplasm	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
44	malignant exocrine pancreas neoplasm	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
45	lung cancer susceptibility 3	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
46	pancreatic ductal adenocarcinoma	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
47	head and neck cancer	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
48	peripheral nervous system neoplasm	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
49	male reproductive system disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
50	upper respiratory tract disease	10.7	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155

Graphical network of the top 20 diseases related to Urinary System Disease:

Sources

Symptoms & Phenotypes for Urinary System Disease

UMLS symptoms related to Urinary System Disease:

dysuria; polyuria; urgency of micturition; other and unspecified genitourinary symptoms; renal colic; pain in urethra; uti symptoms; urethral burning on micturition; loin pain; ureteral pain; flank tenderness; difficulty passing urine; urinary tenesmus; burning urination; bladder discomfort; renal pain; urologic problem

Sources

Drugs & Therapeutics for Urinary System Disease

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Uric acid

Investigational

Phase 4

69-93-2

1175

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Vitamins

Phase 4

Trace Elements

Phase 4

Hematinics

Phase 4

Micronutrients

Phase 4

Anesthetics, Local

Phase 4

Analgesics, Opioid

Phase 4

Narcotics

Phase 4

Tamsulosin

Approved, Investigational

Phase 3

106133-20-4

129211

Mirabegron

Approved

Phase 3

223673-61-8

18319735 9865528

Pregabalin

Approved, Investigational

Phase 3

148553-50-8

5486971

Lomefloxacin

Approved, Investigational

Phase 3

98079-51-7

3948

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Ciprofloxacin

Approved, Investigational

Phase 3

85721-33-1, 93107-08-5

2764

Propiverine

Approved, Investigational

Phase 3

60569-19-9

4942

Anti-Bacterial Agents

Phase 3

Anti-Infective Agents

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

Adrenergic beta-Agonists

Phase 3

Adrenergic beta-3 Receptor Agonists

Phase 3

Adrenergic Agonists

Phase 3

Adrenergic Agents

Phase 3

Solifenacin Succinate

Phase 3

242478-38-2

216457

Muscarinic Antagonists

Phase 3

Cholinergic Antagonists

Phase 3

Cholinergic Agents

Phase 3

Anti-Anxiety Agents

Phase 3

calcium channel blockers

Phase 3

Analgesics

Phase 3

Parasympatholytics

Phase 3

Pharmaceutical Solutions

Phase 2, Phase 3

Paclitaxel

Approved, Vet_approved

Phase 1, Phase 2

33069-62-4

36314

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Docetaxel

Approved, Investigational

Phase 1, Phase 2

114977-28-5

148124

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

Antibiotics, Antitubercular

Phase 2

Neurotransmitter Agents

Phase 2

Alkylating Agents

Phase 2

Albumin-Bound Paclitaxel

Phase 1, Phase 2

Antimitotic Agents

Phase 1, Phase 2

Tubulin Modulators

Phase 1, Phase 2

Immunoglobulins

Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 136)

#	Name	Status	NCT ID	Phase	Drugs
1	Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty	Unknown status	NCT02444013	Phase 4	Folic acid;Placebo
2	Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures	Completed	NCT02805504	Phase 4	Exparel;Marcaine
3	A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures	Recruiting	NCT04826484	Phase 4	Exparel 133 miligrams per 10 milliliter injection;Bupivacaine Hydrochloride
4	Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery	Withdrawn	NCT03591289	Phase 4	NMB with rocuronium bromide
5	Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome	Completed	NCT00239317	Phase 3	Tamusulosin
6	Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome	Completed	NCT00239265	Phase 3	Tamuslosin
7	A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms	Completed	NCT01908829	Phase 3	mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
8	Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot	Completed	NCT03927781	Phase 3	Pregabalin 300mg
9	A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder	Completed	NCT02045862	Phase 3	Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
10	A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder	Completed	NCT01972841	Phase 3	Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
11	A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy	Completed	NCT01638000	Phase 3	Mirabegron;Solifenacin succinate
12	A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults	Completed	NCT00258102	Phase 3	Levofloxacin
13	A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults	Completed	NCT00258089	Phase 3	Levofloxacin
14	Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial	Completed	NCT01530620	Phase 3	Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
15	The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction	Recruiting	NCT04972890	Phase 2, Phase 3
16	An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria	Enrolling by invitation	NCT04042402	Phase 3	DCR-PHXC
17	A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)	Terminated	NCT00384891	Phase 3	Bacillus Calmette-Guérin
18	A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC)	Withdrawn	NCT02254915	Phase 3	Bacillus Calmette-Guérin
19	Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients	Completed	NCT02307487	Phase 2	120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
20	Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells	Completed	NCT02291432	Phase 1, Phase 2
21	Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention	Completed	NCT04555343	Phase 1, Phase 2	Tranexamic acid
22	A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer	Completed	NCT03081858	Phase 1, Phase 2	TSD-001
23	A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria	Completed	NCT03847909	Phase 2	DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
24	A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis	Completed	NCT01613586	Phase 2	ASP3652;Placebo
25	A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.	Completed	NCT01340027	Phase 2	Mirabegron;Solifenacin succinate;Placebo
26	Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.	Completed	NCT03562897	Phase 2
27	A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease	Terminated	NCT04387448	Phase 2	GFB-887;Placebo
28	A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome	Terminated	NCT01060254	Phase 2	Placebo;JNJ-42160443
29	A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy	Terminated	NCT02401542	Phase 1, Phase 2	Vofatamab;Docetaxel;Placebo
30	A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy	Terminated	NCT03123055	Phase 1, Phase 2	B-701;Pembrolizumab
31	An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases	Terminated	NCT04950114	Phase 2	GFB-887
32	A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects	Completed	NCT02052713	Phase 1	Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
33	A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects	Completed	NCT02058576	Phase 1	Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
34	Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients	Completed	NCT01232010	Phase 1	Mirodenafil
35	Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients	Completed	NCT01231997	Phase 1	Udenafil
36	Pilot Study of Mycophenolate Mofetil in Congenital Uropathies	Completed	NCT00193635	Phase 1	mycophenolate mofetil
37	Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study	Recruiting	NCT04731376	Phase 1	Testosterone Cypionate
38	Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions	Not yet recruiting	NCT03899298	Phase 1
39	A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral	Not yet recruiting	NCT03258658	Phase 1
40	Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora	Not yet recruiting	NCT03463239	Phase 1
41	A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma	Terminated	NCT02386111	Phase 1	Combination of varlilumab and sunitinib
42	A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer	Terminated	NCT02543645	Phase 1	Combination of Varlilumab and Atezolizumab
43	The Effectiveness of Virtual Reality (VR) to Reduce Pain and Anxiety During Genitourinary (GU) Scans	Unknown status	NCT04251988
44	Effectiveness of Drainage of the Kidney by Percutaneous Nephrostomy Catheter Placement Vs. Retrograde Double J Catheter Placement in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis	Unknown status	NCT04594161
45	Bladder Morphology Using 2 Different Catheter Designs Foley Catheter vs. Cystosure Urinary Access System	Unknown status	NCT03108079
46	Pharmacology and Physiology of the Lower Urinary Tract	Unknown status	NCT00662064
47	Patient Empowerment for Major Surgery Preparation @ Home: Multimodal Prehabilitation in Major Elective Surgery	Unknown status	NCT04190719
48	The Utility of Enhanced Pre- and Post-surgical Protocols to Prevent the Spread of COVID-19 in a Large Urological Department (UroCovid Study)	Unknown status	NCT04409899
49	Remote Ischemic Conditioning (RIC) to Decrease Post-Operative Complications After Major Abdominal Surgery - A Phase IIa Trial	Unknown status	NCT03234543
50	The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones. A Randomized Clinical Trial	Unknown status	NCT03243682

Search NIH Clinical Center for Urinary System Disease

Sources

Genetic Tests for Urinary System Disease

Genetic tests related to Urinary System Disease:

#	Genetic test	Affiliating Genes
1	Abnormality of the Urinary System ²⁸

Sources

Anatomical Context for Urinary System Disease

Organs/tissues related to Urinary System Disease:

FMA: Kidney

MalaCards : Kidney, Prostate, Brain, Spinal Cord, Smooth Muscle, Heart, Neutrophil

Sources

Publications for Urinary System Disease

Articles related to Urinary System Disease:

(show top 50) (show all 1166)

#	Title	Authors	PMID	Year
1	Thyroidization in renal allografts. ⁵³ ⁶²	Ito S...Yamaguchi Y	19594588	2009
2	[Implications of beta 2-microglobulin in the detection of associated urinary tract diseases in patients with infiltrative pulmonary tuberculosis]. ⁵³ ⁶²	Malysheva OK...Molodyk AA	12577571	2002
3	Urine detection of survivin and diagnosis of bladder cancer. ⁵³ ⁶²	Smith SD...Altieri DC	11176843	2001
4	[Urinary Tamm-Horsfall protein coating of free cells and its clinical diagnostic significance]. ⁵³ ⁶²	Yin PD...Shong Q	1864173	1991
5	Biomarkers in Urethral Stricture Disease and Benign Lower Urinary Tract Disease. ⁶²	Campbell JG...Vanni AJ	36424081	2023
6	Increased kidney disease mortality among people with AIDS versus the general population: a population-based cohort study in Italy, 2006-2018. ⁶²	Taborelli M...Zucchetto A	36456002	2022
7	Investigation of the effects of three different generations of fluoroquinolone derivatives on antioxidant and immunotoxic enzyme levels in different rat tissues. ⁶²	Donmez F...Dogan A	34601990	2022
8	Urinary Microbiome of Reproductive-Age Asymptomatic European Women. ⁶²	Ugarcina Perovic S...Peixe L	36383025	2022
9	Exertional hemolysis and hematuria in a Labrador Retriever dog. ⁶²	Saint-Pierre LM...Wun MK	36184929	2022
10	Comparison of bidirectional barbed versus conventional monofilament suture material for closure of feline perineal urethrostomies. ⁶²	Schubmehl SR...Salas NM	36325412	2022
11	Short-term exposure to ozone and cause-specific mortality risks and thresholds in China: Evidence from nationally representative data, 2013-2018. ⁶²	Chen C...Shi X	36470122	2022
12	Comparative evaluation of selected serum and urine biomarkers in cats with interstitial and bacterial cystitis. ⁶²	Gulersoy E...Sayin Z	36345051	2022
13	Diagnostic effectiveness of stress biomarkers in cats with feline interstitial and bacterial cystitis. ⁶²	Gulersoy E...Sayin Z	36436835	2022
14	Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in dogs with lower urinary tract urothelial carcinoma. ⁶²	Weinekotter J...Heilmann RM	36411489	2022
15	Critical size of kidney stone through ureter: A mechanical analysis. ⁶²	Liu Y...Lu TJ	36115174	2022
16	Factors associated with low-compliance bladder in end-stage renal disease patients and development of a clinical prediction model for urodynamic evaluation: the DUDi score. ⁶²	Tangpaitoon T...Swatesutipun V	36307573	2022
17	Urinary interleukin-6 is a potentially useful diagnostic and prognostic marker of acute kidney injury in dogs. ⁶²	Chen H...Segev G	36030370	2022
18	Chromatographic Techniques and Pharmacological Analysis as a Quality Control Strategy for Serjania triquetra a Traditional Medicinal Plant. ⁶²	Aguilar-Guadarrama AB...Avila-Villarreal G	36297401	2022
19	Use of feeding tubes in 112 cats in an internal medicine referral service (2015-2020). ⁶²	Brunet A...Hugonnard M	35833503	2022
20	Protocol for the generation and expansion of human iPS cell-derived ureteric bud organoids. ⁶²	Ryosaka M...Osafune K	35769929	2022
21	The Effect of Patient Positioning on Ureteral Efflux During Intraoperative Cystoscopy: a Randomized Controlled Trial. ⁶²	Galhotra S...Mourad J	36103970	2022
22	Prospective comparison of prostatic aspirate culture and cystocentesis urine culture for detection of bacterial infection in dogs with prostatic neoplasia. ⁶²	Skorupski KA...Burton JH	36167434	2022
23	Multiple Post-SARS-COV2 Infectious Complications in Kidney Transplant Recipient. ⁶²	Grzejszczak P...Kurnatowska I	36295531	2022
24	Clinical presentation, videourodynamic characteristics, and treatment outcome in men with interstitial cystitis-like lower urinary tract symptoms. ⁶²	Yu WR...Kuo HC	35804206	2022
25	How Did SARS-CoV-2 Pandemic Affect the Cats' Health in Hatay Province? A retrospective study. ⁶²	Kose SI...Uyanik G	35918018	2022
26	"Parenteral" Diarrhea Associated With Pediatric Urinary Tract Infections: A Retrospective Chart Review. ⁶²	Mellick LB...Kalra S	35413044	2022
27	Urinary culture sensitivity after a single empirical antibiotic dose for upper or febrile urinary tract infection: A prospective multicentre observational study. ⁶²	John G...Genne D	35289297	2022
28	A multicenter study of antimicrobial prescriptions for cats diagnosed with bacterial urinary tract disease. ⁶²	Weese JS...Bergman PJ	34709080	2022
29	Combination of Ligustri Lucidi Fructus with Ecliptae Herba and their phytoestrogen or phytoandrogen like active pharmaceutical ingredients alleviate oestrogen/testosterone-induced benign prostatic hyperplasia through regulating steroid 5-α-reductase. ⁶²	Tao R...Gao X	35636178	2022
30	Alterations of selected serum biochemical and urinary parameters in dogs with chronic enteropathy. ⁶²	Gori E...Marchetti V	36118717	2022
31	The Urogenital System's Role in Diseases: A Synopsis. ⁶²	Zerdan MB...Nagarajan A	35884388	2022
32	Clinical Application of Botulinum Neurotoxin in Lower-Urinary-Tract Diseases and Dysfunctions: Where Are We Now and What More Can We Do? ⁶²	Kuo HC	35878235	2022
33	Fluoxetine-induced urinary retention in a cat. ⁶²	DiCiccio VK...McClosky ME	35966899	2022
34	A nomogram model predicting the risk of postpartum stress urinary incontinence in primiparas: A multicenter study. ⁶²	Cheng H...Gao H	35779903	2022
35	Ethnobotany of medicinal plants used by the Yao people in Gongcheng County, Guangxi, China. ⁶²	Lu Z...Xu W	35729593	2022
36	Endogenous Fungal Endophthalmitis: Causative Organisms, Treatments, and Visual Outcomes. ⁶²	Chen KJ...Lai CC	35736124	2022
37	Obstructed hemivagina with ipsilateral renal and urinary tract anomaly presenting as an unusual cause of acute abdomen: a radiologic perspective. ⁶²	Mendoza KIR...Nicer DPC	35760501	2022
38	Clinical use and complications of percutaneous cystostomy pigtail catheters in 25 cats. ⁶²	Nurra G...Friend E	35363097	2022
39	Outcomes and postoperative complications after transpelvic urethrostomy used as first-line surgery in 38 male cats with obstructive lower urinary tract disease. ⁶²	Dumartinet C...Bernarde A	34431736	2022
40	Small ruminant urinary obstruction: decision trees for treatment. ⁶²	Mejia S...Fubini SL	35442905	2022
41	Ureteral Endoscopy to Detect Upper Urinary Tract Diseases in Horses. ⁶²	Busechian S...Gialletti R	35172197	2022
42	Proximity to petrochemical industrial parks and risk of chronic glomerulonephritis. ⁶²	Chin WS...Guo YL	35016869	2022
43	Investigation of the Relationship between Colistin Resistance and Capsule Serotypes in Carbapenem Resistant Klebsiella pneumoniae Strains. ⁶²	Baykara B...Koksal F	35699561	2022
44	Dual-Energy CT applications in urinary tract cancers: an update. ⁶²	Bicci E...Miele V	35442120	2022
45	[Incidence and cause of abnormal cholesterol in children aged 2-18 years in a single center]. ⁶²	Yan H...Yan CL	35435182	2022
46	Epidemiological investigations on microbial infection and crystals causing feline lower urinary tract disease in tomcats in Ismailia, Egypt. ⁶²	Mahmoud AE...Soliman ES	35603074	2022
47	Ultrasonographic detection of apex nodules in the urinary bladder of Scottish Terriers. ⁶²	Heng HG...Knapp DW	34989093	2022
48	Stem Cell Application for Stress Urinary Incontinence: from Bench to Bedside. ⁶²	Liu M...Fu Q	35249506	2022
49	Acute-phase proteins in cats with obstructive feline lower urinary tract disease. ⁶²	Dinallo HR...Guimaraes-Okamoto PTC	35191061	2022
50	Prevalence of positive urine culture in the presence of inactive urine sediment in 1049 urine samples from dogs. ⁶²	Strachan NA...Fischer JR	35108434	2022

Sources

Genes for Urinary System Disease

Genes related to Urinary System Disease (0 elite genes):

(show top 50) (show all 120)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	B2M	Beta-2-Microglobulin	Protein Coding	17.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9024089 12577571
2	MIR199A1	MicroRNA 199a-1	RNA Gene	16.06	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
3	SIX1	SIX Homeobox 1	Protein Coding	15.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20110314 16971658
4	UMOD	Uromodulin	Protein Coding	13.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19594588 1864173
5	MIR21	MicroRNA 21	RNA Gene	12.94	DISEASES inferred ¹⁴ ¹⁴
6	NAGLU	N-Acetyl-Alpha-Glucosaminidase	Protein Coding	12.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8283554 1750765
7	H2AC18	H2A Clustered Histone 18	Protein Coding	12.63	DISEASES inferred ¹⁴ ¹⁴
8	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	12.49	DISEASES inferred ¹⁴ ¹⁴
9	MIR145	MicroRNA 145	RNA Gene	12.23	DISEASES inferred ¹⁴ ¹⁴
10	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	12.17	DISEASES inferred ¹⁴ ¹⁴
11	MIR126	MicroRNA 126	RNA Gene	12.04	DISEASES inferred ¹⁴ ¹⁴
12	MIR17	MicroRNA 17	RNA Gene	11.95	DISEASES inferred ¹⁴ ¹⁴
13	MIR142	MicroRNA 142	RNA Gene	11.78	DISEASES inferred ¹⁴ ¹⁴
14	MIR193A	MicroRNA 193a	RNA Gene	11.66	DISEASES inferred ¹⁴ ¹⁴
15	KLK3	Kallikrein Related Peptidase 3	Protein Coding	11.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15452450 7544063 1720942 (more) 1693455 1726942 11176843
16	MIR30A	MicroRNA 30a	RNA Gene	11.65	DISEASES inferred ¹⁴ ¹⁴
17	KRT20	Keratin 20	Protein Coding	11.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10765100 19300416
18	MIR144	MicroRNA 144	RNA Gene	11.51	DISEASES inferred ¹⁴ ¹⁴
19	CFHR2	Complement Factor H Related 2	Protein Coding	11.44	DISEASES inferred ¹⁴ ¹⁴
20	MIR155	MicroRNA 155	RNA Gene	11.32	DISEASES inferred ¹⁴ ¹⁴
21	MIR210	MicroRNA 210	RNA Gene	11.29	DISEASES inferred ¹⁴ ¹⁴
22	MIR214	MicroRNA 214	RNA Gene	11.26	DISEASES inferred ¹⁴ ¹⁴
23	MIR9-1	MicroRNA 9-1	RNA Gene	11.23	DISEASES inferred ¹⁴ ¹⁴
24	MIR143	MicroRNA 143	RNA Gene	11.2	DISEASES inferred ¹⁴ ¹⁴
25	MIR150	MicroRNA 150	RNA Gene	11.19	DISEASES inferred ¹⁴ ¹⁴
26	MIR204	MicroRNA 204	RNA Gene	11.17	DISEASES inferred ¹⁴ ¹⁴
27	MIR125A	MicroRNA 125a	RNA Gene	11.17	DISEASES inferred ¹⁴ ¹⁴
28	MIR221	MicroRNA 221	RNA Gene	11.13	DISEASES inferred ¹⁴ ¹⁴
29	MIR29B1	MicroRNA 29b-1	RNA Gene	11.13	DISEASES inferred ¹⁴ ¹⁴
30	MIR141	MicroRNA 141	RNA Gene	11.11	DISEASES inferred ¹⁴ ¹⁴
31	MIR34A	MicroRNA 34a	RNA Gene	11.1	DISEASES inferred ¹⁴ ¹⁴
32	MIR146A	MicroRNA 146a	RNA Gene	11.1	DISEASES inferred ¹⁴ ¹⁴
33	MIR139	MicroRNA 139	RNA Gene	11.08	DISEASES inferred ¹⁴ ¹⁴
34	MIR29C	MicroRNA 29c	RNA Gene	11.07	DISEASES inferred ¹⁴ ¹⁴
35	SERPINA3	Serpin Family A Member 3	Protein Coding	11.05	DISEASES inferred ¹⁴ ¹⁴
36	MIR192	MicroRNA 192	RNA Gene	11.05	DISEASES inferred ¹⁴ ¹⁴
37	MIR423	MicroRNA 423	RNA Gene	11.02	DISEASES inferred ¹⁴ ¹⁴
38	MIR140	MicroRNA 140	RNA Gene	11.01	DISEASES inferred ¹⁴ ¹⁴
39	MIR223	MicroRNA 223	RNA Gene	10.97	DISEASES inferred ¹⁴ ¹⁴
40	MIR93	MicroRNA 93	RNA Gene	10.95	DISEASES inferred ¹⁴ ¹⁴
41	MIR29A	MicroRNA 29a	RNA Gene	10.94	DISEASES inferred ¹⁴ ¹⁴
42	MIR200A	MicroRNA 200a	RNA Gene	10.9	DISEASES inferred ¹⁴ ¹⁴
43	MIR149	MicroRNA 149	RNA Gene	10.82	DISEASES inferred ¹⁴ ¹⁴
44	MIR185	MicroRNA 185	RNA Gene	10.76	DISEASES inferred ¹⁴ ¹⁴
45	MIR23B	MicroRNA 23b	RNA Gene	10.74	DISEASES inferred ¹⁴ ¹⁴
46	MIR195	MicroRNA 195	RNA Gene	10.74	DISEASES inferred ¹⁴ ¹⁴
47	MIR486-1	MicroRNA 486-1	RNA Gene	10.74	DISEASES inferred ¹⁴ ¹⁴
48	ALDOA	Aldolase, Fructose-Bisphosphate A	Protein Coding	10.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1509638 8486529
49	MIR200C	MicroRNA 200c	RNA Gene	10.66	DISEASES inferred ¹⁴ ¹⁴
50	MIR23A	MicroRNA 23a	RNA Gene	10.62	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Urinary System Disease

ClinVar genetic disease variations for Urinary System Disease:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	CHD1L	NM_004284.6(CHD1L):c.234C>T (p.Thr78=)	SNV	Uncertain Significance	625178	rs1311096135	GRCh37: 1:146724384-146724384 GRCh38: 1:147252729-147252729

Sources

Expression for Urinary System Disease

Search GEO for disease gene expression data for Urinary System Disease.

Sources

Pathways for Urinary System Disease

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	11.16	MIR21 MIR17 MIR145
2	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.15	MIR199A1 MIR17 MIR155 MIR145
3	miRNAs involvement in the immune response in sepsis ⁷⁴	10.81	MIR21 MIR199A1 MIR155 MIR145 MIR126

Sources

GO Terms for Urinary System Disease

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10.03	UMOD MIR30A MIR21 MIR199A1 MIR17 MIR144
2	RISC complex	GO:0016442	9.58	MIR30A MIR21 MIR199A1 MIR17 MIR155 MIR145
3	extracellular vesicle	GO:1903561	9.35	MIR30A MIR21 MIR193A MIR17 MIR126

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.88	MIR21 MIR199A1 MIR17 MIR155 MIR144
2	positive regulation of angiogenesis	GO:0045766	9.8	MIR30A MIR21 MIR199A1 MIR126
3	negative regulation of angiogenesis	GO:0016525	9.72	MIR21 MIR193A MIR145 KLK3
4	negative regulation of inflammatory response	GO:0050728	9.67	MIR199A1 MIR145 MIR142 MIR126
5	miRNA-mediated gene silencing	GO:0035195	9.58	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
6	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.46	MIR199A1 MIR17
7	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.43	MIR21 MIR17
8	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.43	MIR145 MIR199A1 MIR21
9	positive regulation of metalloendopeptidase activity	GO:1904685	9.4	MIR21 MIR17
10	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.35	MIR21 MIR17 MIR145 MIR144 MIR126
11	positive regulation of cellular response to hypoxia	GO:1900039	9.16	MIR21 MIR145

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.65	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155
2	mRNA base-pairing translational repressor activity	GO:1903231	9.32	MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR155